Premium
A phase II randomized study comparing sequential and combined intraarterial cisplatin and radiation therapy in primary brain tumors: A southwest oncology group study
Author(s) -
Mortimer Joanne E.,
Crowley John,
Eyre Harmon,
Weiden Paul,
Eltringham James,
Stuckey W. J.
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.2820690525
Subject(s) - medicine , concomitant , cisplatin , radiation therapy , chemotherapy , surgery , oncology
The Southwest Oncology Group conducted a trial of intraarterial cisplatin (150 mg intravenously every 21 days for 2 doses) administered concomitant with or before radiation therapy. Because of technical difficulties cannulating the artery, 27 of 33 eligible patients were able to receive the cisplatin by arterial injection. Five patients died before completion of the study, and 11 patients in each treatment arm were evaluable for response. Three patients (27%) had an objective tumor regression in each treatment arm. Thromboembolic problems complicated 8 of 57 (14%) chemotherapeutic courses. The median survival for the 33 eligible patients was comparable for both groups: 10.8 months in the concomitant treatment arm and 9.6 months with sequential therapy. Problems related to drug administration and toxicity made it impossible to determine the role of intraarterial cisplatin in the initial management of primary high‐grade gliomas.